Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others

CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain works for radiopharmaceuticals. He walks us through the science behind these medicines before highlighting ITM's pipeline.